Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy

Introduction: The addition of durvalumab after chemoradiation therapy (CRT) in unresectable stage III NSCLC significantly improves survival. The benefit of this approach in elderly patients is controversial given the toxicity associated with CRT and, thus, may be underutilized. We sought to investig...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Sally C.M. Lau, MD, MPH, Malcolm Ryan, BSc, Jessica Weiss, PhD, Aline Fusco Fares, MD, Miguel Garcia, MD, Sabine Schmid, MD, Shelley Kuang, MD, Deirdre Kelly, MB BCh BAO, Ming Sound Tsao, MD, Penelope A. Bradbury, MB BCh, Byoung Chun J. Cho, MD, Alexander Sun, MD, Srinivas Raman, MD, Andrew Hope, MD, Meredith Giuliani, MBBS, MEd, PhD, Benjamin H. Lok, MD, PhD, Andrea Bezjak, MD, Geoffrey Liu, MD, MSc, Natasha B. Leighl, MD, MSc, Frances A. Shepherd, MD, Adrian G. Sacher, MD, MMSc
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2021-12-01
Serie:	JTO Clinical and Research Reports
Soggetti:	Elderly Chemoradiotherapy Immune checkpoint inhibitors Multimodality treatment Safety
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2666364321001107
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!